Want to see JP:4893 full AI Analyst Report?

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥83.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)254.62K

Market Cap

¥3.69B

Enterprise Value¥1.70B

Total Cash (Recent Filing)¥3.54B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.40

Shares Outstanding43,399,117

10 Day Avg. Volume341,430

30 Day Avg. Volume254,623

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-18.33

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe absence of debt reduces leverage and refinancing pressure, giving the company greater financial flexibility than a similarly loss-making business with borrowings. Although continued losses may erode equity, the conservative capital structure provides a durable buffer against interest obligations and debt-related distress.

Consistently High Gross MarginA gross margin near 100% indicates that reported revenue carries limited direct cost burden, preserving substantial contribution before operating expenses. If revenue recovers, this cost structure could provide operating leverage, although current sales levels remain insufficient to cover the company’s broader expenses.

Some Improvement In Losses And Cash BurnImprovement in both annual loss and cash burn offers evidence that deterioration was not uniformly worsening in the latest reported period. This does not establish profitability, but sustained progress could extend the company’s funding runway and improve the prospects for eventual operating stabilization.

Bears Say

Sharp Revenue ContractionRepeated revenue contraction weakens the commercial foundation of the business and makes fixed operating costs harder to absorb. The volatility also reduces visibility into sustainable demand, limiting the company’s ability to scale efficiently, fund development internally, or build a dependable earnings base.

Deep And Persistent UnprofitabilityLarge recurring losses and deeply negative margins show that the current business model is not covering its operating cost base. Unless revenue growth or expense discipline changes materially, ongoing losses can consume equity, weaken financial resilience, and delay the transition to self-sustaining operations.

Persistent Operating Cash BurnConsistently negative operating cash flow means the company has not yet generated cash from its operations, even after reported revenue. Dependence on existing cash or equity funding raises financing risk without debt, because prolonged burn can reduce resources available for development and commercialization.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥83.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥3.69B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is Nov 13, 2026 which is in 12 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Aug 13, 2026. The company reported -¥5.05 earnings per share for the quarter, beating the consensus estimate of -¥5.51 by ¥0.46.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,399,117 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥5.05 in its last earnings report, beating expectations of -¥5.51. Following the earnings report the stock price went up 0.714%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.